Top

Published in:

01-02-2020 | Nimodipine | Practical Pearl

Reversible Cerebral Vasoconstriction Syndrome Responsive to Intravenous Milrinone

Authors: Maximiliano A. Hawkes, Alejandro A. Hlavnicka, Nestor A. Wainsztein

Published in: Neurocritical Care | Issue 1/2020

Excerpt

Reversible cerebral vasoconstriction syndrome (RCVS) causes reversible multifocal constriction of cerebral arteries. It is triggered by several conditions, including vasoactive medications, postpartum, migraine, hypertension, and arterial dissection [1]. Suspension of the precipitating agent, supportive care, and oral calcium channel blockers are the mainstay of treatment for most patients [2]. However, the development of refractory vasospasm, ischemic stroke, or intracerebral hemorrhage (ICH) may require further interventions, including intravenous (IV) or intra-arterial vasodilators and balloon angioplasty [2]. Yet, evidence for all these treatment options is weak and is based on case reports, case series, and expert’s opinion. We report a case of severe postpartum RVCS complicated by ICH successfully treated with IV milrinone infusion. …

Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11(10):906–17. https://doi.org/10.1016/S1474-4422(12)70135-7.CrossRefPubMed

Cappelen-Smith C, Calic Z, Cordato D. Reversible cerebral vasoconstriction syndrome: recognition and treatment. Curr Treat Options Neurol. 2017;19(6):21. https://doi.org/10.1007/s11940-017-0460-7.CrossRefPubMed

Purkayastha S, Sorond F. Transcranial Doppler ultrasound: technique and application. Semin Neurol. 2012;32(4):411–20. https://doi.org/10.1055/s-0032-1331812.CrossRefPubMed

Lazaridis C, Czosnyka M. Cerebral blood flow, brain tissue oxygen, and metabolic effects of decompressive craniectomy. Neurocrit Care. 2012;16(3):478–84. https://doi.org/10.1007/s12028-012-9685-1.CrossRefPubMed

Chen S-P, Fuh J-L, Wang S-J, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol. 2009. https://doi.org/10.1002/ana.21951.CrossRefPubMedPubMedCentral

Ducros A, Hajj-Ali RA, Singhal AB, Wang S-J. Reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014;71(3):368. https://doi.org/10.1001/jamaneurol.2013.5875.CrossRefPubMed

Sattar A, Manousakis G, Jensen MB. Systematic review of reversible cerebral vasoconstriction syndrome. Expert Rev Cardiovasc Ther. 2010;8(10):1417–21. https://doi.org/10.1586/erc.10.124.CrossRefPubMedPubMedCentral

Sorensen DM. Reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2016;73(2):232–3. https://doi.org/10.1001/jamaneurol.2015.3472.CrossRefPubMed

Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology. 2017;88(3):228–36. https://doi.org/10.1212/WNL.0000000000003510.CrossRefPubMedPubMedCentral

10.

Singhal AB, Hajj-Ali RA, Topcuoglu MA, et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011;68(8):1005–12. https://doi.org/10.1001/archneurol.2011.68.CrossRefPubMed

11.

Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser M-G. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091–101. https://doi.org/10.1093/brain/awm256.CrossRefPubMed

12.

Chen S-P, Fuh J-L, Lirng J-F, Chang F-C, Wang S-J. Recurrent primary thunderclap headache and benign CNS angiopathy: spectra of the same disorder? Neurology. 2006;67(12):2164–9. https://doi.org/10.1212/01.wnl.0000249115.63436.6d.CrossRefPubMed

13.

Marsh EB, Ziai WC, Llinas RH. The need for a rational approach to vasoconstrictive syndromes: transcranial doppler and calcium channel blockade in reversible cerebral vasoconstriction syndrome. Case Rep Neurol. 2016;8(2):161–71. https://doi.org/10.1159/000447626.CrossRefPubMedPubMedCentral

14.

Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34–44.CrossRefPubMed

15.

Katz BS, Fugate JE, Ameriso SF, et al. Clinical worsening in reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014;71(1):68–73. https://doi.org/10.1001/jamaneurol.2013.4639.CrossRefPubMed

16.

Elstner M, Linn J, Muller-Schunk S, Straube A. Reversible cerebral vasoconstriction syndrome: a complicated clinical course treated with intra-arterial application of nimodipine. Cephalalgia. 2009;29(6):677–82. https://doi.org/10.1111/j.1468-2982.2008.01768.x.CrossRefPubMed

17.

Linn J, Fesl G, Ottomeyer C, et al. Intra-arterial application of nimodipine in reversible cerebral vasoconstriction syndrome: a diagnostic tool in select cases? Cephalalgia. 2011;31(10):1074–81. https://doi.org/10.1177/0333102410394673.CrossRefPubMed

18.

Bouchard M, Verreault S, Gariepy J-L, Dupre N. Intra-arterial milrinone for reversible cerebral vasoconstriction syndrome. Headache. 2009;49(1):142–5. https://doi.org/10.1111/j.1526-4610.2008.01211.x.CrossRefPubMed

19.

Song JK, Fisher S, Seifert TD, et al. Postpartum cerebral angiopathy: atypical features and treatment with intracranial balloon angioplasty. Neuroradiology. 2004;46(12):1022–6. https://doi.org/10.1007/s00234-003-1129-3.CrossRefPubMed

20.

Al-Mufti F, Dodson V, Wajswol E, et al. Chemical angioplasty for medically refractory reversible cerebral vasoconstriction syndrome(). Br J Neurosurg. 2018;32(4):431–5. https://doi.org/10.1080/02688697.2018.1479512.CrossRefPubMed

21.

Fraticelli AT, Cholley BP, Losser M-R, Saint Maurice J-P, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(3):893–8. https://doi.org/10.1161/STROKEAHA.107.492447.CrossRefPubMed

22.

Lannes M, Teitelbaum J, del Pilar Cortes M, Cardoso M, Angle M. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care. 2012;16(3):354–62. https://doi.org/10.1007/s12028-012-9701-5.CrossRefPubMed

23.

Oyama N, Sakaguchi M, Higashida K, et al. Remarkable effect of a phosphodiesterase type 3 inhibitor, milrinone in a reversible cerebral vasoconstriction syndrome patient with ischemic stroke: a case report. J Neurol Sci. 2017;381:642. https://doi.org/10.1016/j.jns.2017.08.1808.CrossRef

24.

Lakhal K, Rodie-Talbere P-A, Alexandre P-L, Testard N, Rozec B, Daumas-Duport B. Continuous intravenous milrinone for severe reversible cerebral vasoconstriction syndrome (a case report). J Neurol Sci. 2019;397:55–7. https://doi.org/10.1016/j.jns.2018.12.027.CrossRefPubMed

Title: Reversible Cerebral Vasoconstriction Syndrome Responsive to Intravenous Milrinone
Authors: Maximiliano A. Hawkes
Alejandro A. Hlavnicka
Nestor A. Wainsztein
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Nimodipine
Milrinone
Published in: Neurocritical Care / Issue 1/2020
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI: https://doi.org/10.1007/s12028-019-00850-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reversible Cerebral Vasoconstriction Syndrome Responsive to Intravenous Milrinone

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Autonomic Dysfunction in Guillain–Barré Syndrome Puts Patients at Risk

Neurocritical Care: A Growing International Collaborative

High-Dose Intravenous Ascorbic Acid: Ready for Prime Time in Traumatic Brain Injury?

Sequential Pneumatic Compression in the Arm in Neurocritical Patients with a Peripherally Inserted Central Venous Catheter: A Randomized Trial

Midline and Parasagittal Seizures are Rare in Adult Patients

Which Spreading Depolarizations Are Deleterious To Brain Tissue?